


Searching News Database: iCo Therapeutics
HSMN NewsFeed - 5 May 2014
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
HSMN NewsFeed - 20 Aug 2013
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
EpiCept Announces Reverse Stock Split and Change of Corporate Name to Immune Pharmaceuticals Inc.
HSMN NewsFeed - 13 Sep 2011
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
HSMN NewsFeed - 22 Jan 2007
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
iCo Therapeutics Receives FDA Clearance to Initiate Clinical Trial in Diabetic Macular Edema
HSMN NewsFeed - 21 Dec 2006
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Isis Development Partner iCo Therapeutics Files IND for Antisense Drug to Treat Eye Disease
Additional items found! 3
Members Archive contains
3 additional stories matching:
iCo Therapeutics
(Password required)
iCo Therapeutics
(Password required)
